Coagulation Parameters
Coagulation Parameters - Related Videos
01:09
Coagulation
0 Views •
2024
The coagulation phase is a critical part of the body's process to prevent blood loss following injury to blood vessels. It involves chemical reactions that form a clot to seal the injured area. The clotting process begins shortly after injury, within 15-20 seconds for severe damage and 1-2 minutes for minor injuries. During the coagulation phase, clotting factors, or procoagulants, play a vital role in initiating and progressing the coagulation cascade. This cascade is a series of reactions...
01:06
Coagulation
0 Views •
2024
Colloidal solids are solid particles suspended in solution. They are usually negatively charged, attracting a compact primary layer of positively charged ions, which attract more counterions to form an electrical double layer. Electrostatic repulsion between the charged double layers prevents the particles from colliding, stabilizing the colloids. These solids are often undesirable because they can contain toxins that are difficult to remove. Coagulation is a technique that helps aggregate and...
12:24
Helical Organization of Blood Coagulation Factor VIII on Lipid Nanotubes
0 Views •
Cited by 9 •
2014
We present a combination of Cryo-electron microscopy, lipid nanotechnology, and structure analysis applied to resolve the membrane-bound structure of two highly homologous FVIII forms: human and porcine. The methodology developed in our laboratory to helically organize the two functional recombinant FVIII forms on negatively charged lipid nanotubes (LNT) is described.
08:14
Modeling Stroke in Mice: Permanent Coagulation of the Distal Middle Cerebral Artery
0 Views •
Cited by 103 •
2014
Various murine models of middle cerebral artery occlusion (MCAO) are widely used in experimental brain research. Here, we demonstrate the model of transcranial permanent distal MCAO which produces consistent cortical infarction of a size corresponding to damage imposed by the majority of human ischemic strokes.
13:08
Measurement of Factor V Activity in Human Plasma Using a Microplate Coagulation Assay
0 Views •
Cited by 10 •
2012
This study describes a novel microplate assay that measures FV coagulation activity during fibrin clot formation in human plasma which has not been reported previously. The method uses a kinetic microplate reader to continuously measure the change in absorbance at 405nm during fibrin clot formation in human plasma.
FAQs
Prothrombin time and its standardized expression, the INR, primarily reflect the extrinsic and common coagulation pathways. Activated partial thromboplastin time evaluates the intrinsic and common pathways. Comparing these measurements helps identify which portion of clot formation may be altered, rather than treating every abnormal result as evidence of the same coagulation problem.
Platelet activity and fibrinogen availability assess important components of clot formation that pathway-based tests may not represent fully. Platelets contribute to the initial hemostatic response, while fibrinogen supports formation of the fibrin component of a clot. Considering these findings alongside pathway measurements provides a broader assessment of hemostasis.
A combined pattern can distinguish whether an abnormality involves platelet activity, fibrinogen availability, or one or more clotting pathways. This broader view supports investigation of bleeding and thrombotic disorders and can also reveal coagulation changes associated with liver-related disease. Interpretation therefore depends on relationships among results, not isolated values.
Clinicians use the results to evaluate whether abnormal hemostasis may contribute to excessive bleeding or thrombosis. Prothrombin time, INR, activated partial thromboplastin time, platelet activity, and fibrinogen availability provide complementary information. Reviewing their combined pattern can help guide diagnostic assessment and clarify which aspect of clot formation requires further attention.
Prothrombin time and INR, along with activated partial thromboplastin time when relevant to the treatment context, provide laboratory information for monitoring anticoagulant therapy. Results can help clinicians assess the effect of treatment and support treatment decisions. Their interpretation remains part of a broader clinical assessment rather than a stand-alone measure of patient status.
Before or during clinical care, combined coagulation findings can help assess the likelihood of bleeding associated with a procedure and inform transfusion planning. Results may also identify changes requiring attention in patients with suspected disorders or liver-related coagulation abnormalities. Using several parameters together supports more appropriate decisions than relying on a single measurement.